What is it about?
Academic scientists are represented disproportionately in publications of clinical trials of pharmaceuticals.
Featured Image
Why is it important?
The solution I propose is not to involve academics more in the design and analysis of drug industry trials but to involve pharmaceutical scientists more in their publication.
Read the Original
This page is a summary of: Authorship of drug industry trials, Pharmaceutical Statistics, June 2002, Wiley,
DOI: 10.1002/pst.11.
You can read the full text:
Resources
Contributors
The following have contributed to this page
